149 related articles for article (PubMed ID: 33727198)
1. Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer.
Tarpgaard LS; Andersen PV; Øgaard N; Demuth C; Andersen CL; Pfeiffer P
Ann Oncol; 2021 Jun; 32(6):805-806. PubMed ID: 33727198
[No Abstract] [Full Text] [Related]
2. Defying all odds in MMR-deficient rectal cancers.
Chalabi M
Cancer Cell; 2022 Sep; 40(9):914-916. PubMed ID: 36055229
[TBL] [Abstract][Full Text] [Related]
3. Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?
Acar T; Acar N; Kamer E; Tekindal MA; Cengiz F; Kar H; Atahan K; Haciyanli M
Updates Surg; 2020 Mar; 72(1):73-82. PubMed ID: 31863279
[TBL] [Abstract][Full Text] [Related]
4. [Changes in the immune status of patients with rectal cancer while using specific immunotherapy].
Zagadarchuk NL; Potebnia GP; Kikot' VA; Shalimov SA; Keĭsevich LV; Litvinenko AA; Kravchenko AV; Kurganova LV; Shalimova TS
Klin Khir; 1995; (9-10):23-6. PubMed ID: 8697208
[No Abstract] [Full Text] [Related]
5. Letter: Immunotherapy for colorectal cancer.
Evans JT
Lancet; 1976 Jun; 1(7971):1248. PubMed ID: 58300
[No Abstract] [Full Text] [Related]
6. Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
Mans L; Pezzullo M; D'Haene N; Van de Stadt J; Van Laethem JL
Eur J Cancer; 2020 Aug; 135():75-77. PubMed ID: 32554216
[No Abstract] [Full Text] [Related]
7. [Chemotherapy and immunotherapy for gastric and colorectal cancer (author's transl)].
Zeitoun P; Martin F
Gastroenterol Clin Biol; 1978 May; 2(5):527-38. PubMed ID: 355039
[No Abstract] [Full Text] [Related]
8. Recent advances in the treatment of rectal cancer.
Nicholls RJ
Br J Hosp Med; 1980 Oct; 24(4):309-10, 312, 315 passim. PubMed ID: 7437620
[No Abstract] [Full Text] [Related]
9. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer.
Huh JW; Kim HR; Kim YJ
Dis Colon Rectum; 2013 Jun; 56(6):698-703. PubMed ID: 23652742
[TBL] [Abstract][Full Text] [Related]
10. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy and transanal endoscopic surgery in T2-T3 superficial, N0, M0 rectal tumors. Local recurrence, complete clinical and pathological response.
Serra-Aracil X; Pericay C; Mora-Lopez L; Garcia Pacheco JC; Latorraca JI; Ocaña-Rojas J; Casalots A; Ballesteros E; Navarro-Soto S
Cir Esp; 2017 Apr; 95(4):199-207. PubMed ID: 28411888
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Immunotherapy in Rectal Cancer Illusion or Nirvana.
Wilson K; Heriot A
Ann Surg Oncol; 2021 Nov; 28(12):7474-7475. PubMed ID: 34115252
[No Abstract] [Full Text] [Related]
13. Contemporary management of rectal cancer: an overview.
Jackson BR
Cancer; 1977 Nov; 40(5):2365-74. PubMed ID: 336187
[No Abstract] [Full Text] [Related]
14. [A case report of locally recurrent rectal cancer after low anterior resection that led to a pathological complete response to neoadjuvant chemoradiotherapy].
Matsushita A; Takemoto H; Ikeda M; Munakata T; Fukunaga M; Kawabata R; Yamamoto T; Oda K; Kishimoto T; Imamura H; Ohzato H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2261-3. PubMed ID: 23268043
[TBL] [Abstract][Full Text] [Related]
15. [Current status in the treatment of rectal cancer in the Czech Republic regarding the rate of complete pathological response after neoadjuvant therapy--PATOD C20 study 2011-2012].
Dušek T; Ferko A; Blaha M; Dušek L; Malúšková D; Örhalmi J; Dolejš J; Vošmik M
Rozhl Chir; 2015 Jul; 94(7):276-82. PubMed ID: 26305346
[TBL] [Abstract][Full Text] [Related]
16. Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion.
Wilkins S; Haydon A; Porter I; Oliva K; Staples M; Carne P; McMurrick P; Bell S
Dis Colon Rectum; 2016 May; 59(5):361-8. PubMed ID: 27050597
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant treatment in surgery of colon and rectal cancer].
Fleischer I; Wainstein R; de Gibson AM
Acta Gastroenterol Latinoam; 1982; 12(2):189-93. PubMed ID: 6818807
[TBL] [Abstract][Full Text] [Related]
18. Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors.
O'Connell MJ; Chen ZJ; Yang H; Yamada M; Massaro M; Mittelman A; Ferrone S
Semin Surg Oncol; 1989; 5(6):441-7. PubMed ID: 2688034
[TBL] [Abstract][Full Text] [Related]
19. Melbourne trial of adjuvant immunotherapy in operable large bowel cancer.
Gray BN; Walker C; Andrewartha L; Freeman S; Bennett RC
Aust N Z J Surg; 1988 Jan; 58(1):43-6. PubMed ID: 3046593
[TBL] [Abstract][Full Text] [Related]
20. The challenge of colorectal cancer.
Mason AY
Proc R Soc Med; 1973 Dec; 66(12):1177-8. PubMed ID: 4777045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
